Allarity Therapeutics, Inc. · NASDAQ:ALLR
Allarity Therapeutics — Investor Presentation (March 2023)
37 slides from Allarity Therapeutics's investor presentation, Mar 9, 2023
Slide 1: Personalized Cancer Care. Realized.
= allarity” THERAPEUTICS Personalized Cancer Care. Realized. James G. Cullem, CEO H1 2023 Nasdaq: ALLR
Slide 2: Legal Statement
Legal Statement This presentation is provided for informational purposes only and is subject to change. The information contained herein does not purport to be all-inclusive. The data contained herein is derived from various internal and external sources, and may rely upon assumptions, stated or oth
Slide 3: Company Snapshot: New Therapeutics for Unmet Cancer Needs
Company Snapshot: New Therapeutics for Unmet Cancer Needs We are building an oncology-focused pharmaceutical company using our first-in-class, highly developed DRP ® companion diagnostics platform to achieve true, personalized cancer care. Si Robust pipeline of 3 clinical-stage cancer Drug Response
Slide 4: Primary Pipeline
Primary Pipeline ‘Secondary Pipeline Pipeline — Advancing Former Big Pharma Therapeutics with DRP® Dovitinib Stenoparib IXEMPRA 2X-111 PHASE 1/1b PHASE 2 PHASE 3 NDA STATUS/ PARTNER Pan-tyrosine kinase inhibitor PARP and tankyrase inhibitor US Approved and out- Microtubule inhibitor licensed to Alla
Slide 5: Personalized Therapy for Cancer Patients Relies on Predictive Diagnostics
Personalized Therapy for Cancer Patients Relies on Predictive Diagnostics to Select Likely Responders to a Given Drug Classical Drug Development Allarity Approach Treat all of the patients Treat only patients sensitive to therapy Low Average High Average Patient Benefit Patient Benefit Helarity: Ala
Slide 6: DRP® is Distinct from Conventional Biomarker Technology
DRP® is Distinct from Conventional Biomarker Technology Conventional Biomarker Approaches Largely Fail to Address Complex Tumor Biology and Mechanisms of Drug Response/Resistance Allarity’s DRP® develops predictive biomarkers based upon complex gene expression analysis Retrospectively & Broadly Sopl
Slide 7: How Allarity Approaches the Complexity of Cancer
How Allarity Approaches the Complexity of Cancer Cancer is Complex “Systems biology” is used to analyze all genes (~25,000) expressed in a cancer cell/tumor, without bias towards current knowledge of relevant drug targets or pathways. ‘Graph ofall 680 non-redundant proteins The Tumor Tells us What i
Slide 8: How a Drug-Specific DRP® Signature is Created
How a Drug-Specific DRP® Signature is Created Example: Dovitinib ee ee ee ee SS SSS SSS ES tenseritome SSS SS SS SS tezttretin 0 co + Proprietary and highly advanced statistical and computational biology SES SESE] Kerrewn methodologies are applied to correlate cell growth in vitro after treatment wi
Slide 9: DRP® Companion Diagnostics: Predicting a Cancer Patient's Drug Response
DRP® Companion Diagnostics: Predicting a Cancer Patient's Drug Response Step 1 | Step2_ Patients’ biopsy samples Compare patients’ tumor gene Identify patients with high DRP® expression to DRP® signature score for a given drug a ° PATIENTS! TUMORS. Helarity- Alarty Therapeutics
Slide 10: DRP® CDx Sample Collection Kits
DRP® CDx Sample Collection Kits Pallarity- 10
Slide 11: DRP® Platform: Extensively Studied in Clinical Trials
DRP® Platform: Extensively Studied in 47 Clinical Trials* PROSPECTIVE CLINICAL TRIALS — PHASE 2 DRP® Clinical Impact Cisplatin/LiPlaCis® Phase 2 study (n=37) completed — late-stage metastatic BC 2-5 fold increase in Stenoparib Phase 2 study (n=30) underway — 3” line ovarian cancer ORR or TTP between
Slide 12: DRP® Companion Diagnostics Can Support External Drug Programs
DRP® Companion Diagnostics Can Support External Drug Programs Broad potential to partner with other oncology therapeutics developers (including Big Pharma) to develop drug-specific DRP® companion Dx for their pipeline programs. DRP® companion Dx can be developed and used to support: , + Phase 1/1b c
Slide 13: Primary Pipeline
x allarity” Primary Pipeline _ Dovitinib Stenoparib IXEMPRA® ol
Slide 14: Dovitinib: A Pan-Tyrosine Kinase Inhibitor (TKI)
Dovitinib: A Pan-Tyrosine Kinase Inhibitor (TKI) Annual sales" in 5 large indications where + Exclusively in-licensed from Novartis. Pan-Tyrosine Kinase Inhibitor (TKI), Dovitinib hag shown cal activity small molecule, targeted inhibitor of FGFR, VEGFR, and other RTKs. USS Bn Unique, inhibitory prof
Slide 15: Validated Dovitinib-DRP® Identifies Dovitinib-Responsive mRCC Patients
Validated Dovitinib-DRP® Identifies Dovitinib-Responsive but not Sorafenib-Responsive mRCC Patients Kaplan-Meier Plot ~ Overall Survival -Entire arms 34 HR = 0.96 (95%CI 0.75-1.22) Survival probability oO b arm but not in sorafenib arm Dov arm DAP+ (N=49, median 16.0 mo) Dov arm DRP- (N=86, median 9
Slide 16: Dovitinib: Combination Therapy Opportunity with Stenoparib (PARPi)
Dovitinib: Combination Therapy Opportunity with Stenoparib (PARPi) ? ee ; : Treatment setting = 2" line or later therapy in ovarian cancer (OC). ‘Annual sales! (USSm) in indications + Prior clinical trials have shown promising synergy between PARPi targeted by Stenoparib with DRP® and TKIs. +2000 +
Slide 17: Dovitinib: Potential Combination Therapy with Immune Checkpoint Inhibitors
Dovitinib: Potential Combination Therapy with Immune Checkpoint Inhibitors (anti-PD-1, anti-CTLA-4) * Treatment setting = Front-line to 3" line treatment in solid tumors where Pembro is approved. * Pembrolizumab (KEYTRUDA®) is currently standard-of-care in 14+ indications, both in mono- and combinat
Slide 18: Stenoparib: A Dual PARP and Tankyrase Inhibitor
Stenoparib: A Dual PARP and Tankyrase Inhibitor Annual sales‘ (US$m) in indications targeted by Stenoparib with DRP® + Exclusively in-licensed from Eisai. First-in-class small molecule targeted inhibitor of DNA damage repair enzymes (PARP) with dual Tankyrase inhibitor activity (Wnt signaling). fea
Slide 19: Stenoparib-DRP® Identifies Responsive Patients
Stenoparib-DRP® Identifies Responsive Patients Results of Phase | Trial Be Response rate | | Response rate 5 below DRP® above DRP® 8 cutoff of 50: cutoff of 50: ae 0% (0 of 7) 33% (2 of 6) 3 l. 5 F Be a 2 a z8 s 3 Response rate without DRP: z 15% (2/13) Bo 0=0.42, P:0.07 a All 8 histologies espera o
Slide 20: Stenoparib: Well Positioned in PARPi Competitive Landscape
Stenoparib: Well Positioned in PARPi Competitive Landscape the identification of reliable biomarkers will be critical for the success of this targeted agent” * Export | Absence of a Strong opportunity Slapatt, Astrazeneca? Agpecved BREA Niraparib fest QFTESARO Approved «= BRCAHRD Rucaparib Approved
Slide 21: IXEMPRA® (Ixabepilone): A Microtubule Inhibitor
IXEMPRA® (Ixabepilone): A Microtubule Inhibitor + Exclusively in-licensed for EU from R-PHARM U.S. Microtubule Inhibitor, originally developed and marketed by Bristol Myers Squibb. . Ixempra® in the U.S. + Approved & marketed in U.S. for the treatment of mBC: + in combination with capecitabine for t
Slide 22: IXEMPRA®-DRP® Nearly Doubles ORR in Neoadjuvant BC
IXEMPRA®-DRP® Nearly Doubles ORR in Neoadjuvant BC 1) Perez ta (2007) in mBC paints ossant lo antacyelin, axane, and capectabine 2) Thomas eta! (2007) n BC patenis estan axanes Estimated ORR in DRP+ patients Ixempra® DRP® selected patients ORR 20% (CBR* 41%) No previous taxane therapy With previous
Slide 23: Partnered Secondary Pipeline Programs
Partnered Secondary Pipeline Programs We have monetized our prior secondary pipeline programs through external partnerships LiPlaCis® out-licensed to Chosa Oncology AB (an affiliate of Smerud Medical Research Int'l) in April 2022 for further clinical & commercial development in connection with cispl
Slide 24: Multiple Commercial Partnership Opportunities
Multiple Commercial Partnership Opportunities + Commercialization strategy: leverage marketing partnerships with leading global or regional oncology therapeutics companies to achieve optimal market penetration in key markets. + Potentially interested partners identified in: + EU region * US. + MENA
Slide 25: Pipeline Development 2023-2025
Pipeline Development 2023-2025 SS SS A [ S Pediatric Osteosarcoma: ‘Mono-therapy (with OneoHeroes) Phase 1b Phase 2 Combo Rx Study #2: TBD f ‘ ‘with immune checkpoint inhibitor H Phase 2 (N=120+) a (subject tad! untng) varian Cancer (2tine orate : >» Combo Rx study with Stenoparib Phase 2 (N-120+) »
Slide 26: ee: larity~
ee: larity~ THERAPEUTICS #
Slide 27: Our Senior Leadership Team
Our Senior Leadership Team James G. Cullem, J.D. Chief Executive Officer Joan Y. Brown, CPA Steen Knudsen, Ph.D Chief Financial Officer Chief Scientific Officer, Co-Founder Thomas Jensen SVP of Investor Relations, Co-Founder Marie Foegh, MD Chief Medical Officer x allarity~ Alarty Therapeutics
Slide 28: Our Scientific Advisory Board
Our Scientific Advisory Board Dan von Hoff, JD Joyce A. O’Shaughnessy, MD Physician in Chief, Distinguished Professor Co-Chair of Breast Cancer Research and MAYO. athe Translational Genomics Research Sati piesa Caen Donon CLINIC Institute (TGen) in Phoenix, Arizona. Virginia . Research at Baylor-Sam
Slide 29: Our Board of Directors
Our Board of Directors Jerry McLaughlin 5 David A. Roth Chairman Non-Executive Director CEO of Life Biosciences, Inc. Prior CMO of Syros Pharmaceuticals, GEO and Board Member of Neos Inc. Prior CMO of infinity Therapeutics as well as previous | Pharmaceuticals, ne., and VP, CEO, President and Board
Slide 30: Upcoming Milestones to Deliver Significant Value Creation
Upcoming Milestones to Deliver Significant Value Creation Delivering significant value over the next 12-18 months through multiple value-creating inflection points Dovitinib Initiate 1st combo Rx study (with Stenoparib) for OC in Q2 2023. Stenoparib Anticipated Phase 1b data readout H1 2024. Initiat
Slide 31: Unlocking the Value of a Precision Oncology Pipeline
Unlocking the Value of a Precision Oncology Pipeline Comparable Public Equities $951M Us. Nasdeq $308M deollar Listed Equities $102M $62M — —— Evie a g g g = 2 | : i = g : z € . 2 2 2 5 2 4 e 5 3 5 2 Most advanced stage Phase‘ Phase2 ~«—=«Phase3.-—=«~Phase3 | Phase2 Number of assets Fi 3 2 3 in clin
Slide 32: Key Investment Highlights
Key Investment Highlights De-risked, former Big Pharma oncology pipeline with multiple mid-clinical-stage drug candidates and opportunities for external partnering and/or acquisitions. Key value inflection points in 12-18 months. Interim data readouts for lead clinical programs in H2 2023 and H1 202
Slide 33: allarity”
allarity” THERAPEUTICS James G. Cullem Chief Executive Officer +1 (978) 500-0863 jcullem@allarity.com allarity.com
Slide 34: FAQs About Our DRP® Platform Technology
FAQs About Our DRP® Platform Technology A: They represent (i) our proprietary correlation analysis, (ii) our proprietary clinical biopsy filter, and (iii) our final statistical refinement step. A: Because our 35+ prior clinical validations for DRP® have proven that selecting the top 50% of patients,
Slide 35: FAQs About Our DRP® Platform Technology
FAQs About Our DRP® Platform Technology A: Both. We have completed 35+ retrospective validations (including blinded retrospective validations) and 1 prospective validation to date. A: No. We typically receive standard formalin-fixed, paraffin-embedded (FFPE) biopsy material, from which we extract al
Slide 36: DRP® Platform: Clinical Validations, Drugs/Combos
DRP® Platform: 47 Clinical Validations, 32 Drugs/Combos Cispiatin/Lracis Fulvestrant Dovitnis Dovitnib Epicubicia Belinostat Exemestane 2X121 PARP Tamoxifen Docetaxel Cis-EpiCap ‘VOCMA. ‘ABVD Decitabine “Tarceva Soraferib ‘Cetuximab Bortezomib ‘Melphalan Paclitaxel Doc-eye ‘Anastrozale FOLFOX/FOLFIR
Slide 37: Publications of Clinical/Method Validation for Drug-Specific DRP®'s
Publications of Clinical/Method Validation for Drug-Specific DRP®’s Chen J, etal. A TH-gene signature of TRAIL sensitivity in eancer cells. (October 2011); Mo! Cancer Ther, 10.1158/1S35-7163, Wang W, etal. Independent validation of a model us chemoser 1g cel to predict response to therapy..J Nat! Ca
Allarity Therapeutics — Investor Presentation (March 2023) on 6ix